89Bio Inc
ETNB9.230USD
+0.070+0.76%
交易中 （美東）報價延遲15分鐘
1.35B總市值
虧損本益比TTM
關於 89Bio Inc 公司
89bio, Inc. 是一家臨牀階段的生物製藥公司。該公司專注於開發和商業化治療肝臟和心臟代謝疾病的療法。該公司的主要候選產品 pegozafermin 是一種經過特殊設計的成纖維細胞生長因子 21 (FGF21) 糖基化聚乙二醇化類似物，正在開發用於治療非酒精性脂肪性肝炎 (NASH) 和嚴重高甘油三酯血癥 (SHTG)。Pegozafermin 經過設計可防止蛋白水解並降低腎臟清除率並優化其效力，從而可以使用較低的劑量/劑量。Pegozafermin 已通過用天然氨基酸取代位於激素 C 末端的位點特定位置 (173 和 176) 的兩個突變而最佳構建。該公司進行了一項 I 期臨牀試驗，以評估 pegozafermin 的安全性、耐受性和藥代動力學 (PK)。
公司簡介
公司代碼ETNB
公司名稱89Bio Inc
上市日期Nov 11, 2019
CEOMr. Rohan Palekar
員工數量93
證券類型Ordinary Share
年結日Nov 11
公司地址655 Montgomery Street
城市SAN FRANCISCO
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編94111
電話14154329270
網址https://www.89bio.com/
公司代碼ETNB
上市日期Nov 11, 2019
CEOMr. Rohan Palekar
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Rohan Palekar
Mr. Rohan Palekar
Chief Executive Officer, Director
Chief Executive Officer, Director
312.57K
-51.62%
Mr. Quoc Le-Nguyen
Mr. Quoc Le-Nguyen
Chief Technical Operations Officer
Chief Technical Operations Officer
102.83K
-9.23%
Mr. Francis Willard Sarena, CPA., J.D.
Mr. Francis Willard Sarena, CPA., J.D.
Chief Operating Officer
Chief Operating Officer
78.75K
+215.00%
Mr. Ryan Martins
Mr. Ryan Martins
Chief Financial Officer
Chief Financial Officer
43.67K
-16.29%
Dr. Charles A. McWherter, Ph.D.
Dr. Charles A. McWherter, Ph.D.
Independent Director
Independent Director
25.00K
+150.00%
Ms. Kathleen D. Laporte
Ms. Kathleen D. Laporte
Independent Director
Independent Director
--
--
Ms. Lota S. Zoth, CPA
Ms. Lota S. Zoth, CPA
Independent Director
Independent Director
--
--
Dr. Steven M. (Steve) Altschuler, M.D.
Dr. Steven M. (Steve) Altschuler, M.D.
Independent Chairman of the Board of Director
Independent Chairman of the Board of Director
--
--
Dr. Derek Paul Di Rocco, Ph.D.
Dr. Derek Paul Di Rocco, Ph.D.
Independent Director
Independent Director
--
--
Dr. Hank Mansbach, M.D.
Dr. Hank Mansbach, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Rohan Palekar
Mr. Rohan Palekar
Chief Executive Officer, Director
Chief Executive Officer, Director
312.57K
-51.62%
Mr. Quoc Le-Nguyen
Mr. Quoc Le-Nguyen
Chief Technical Operations Officer
Chief Technical Operations Officer
102.83K
-9.23%
Mr. Francis Willard Sarena, CPA., J.D.
Mr. Francis Willard Sarena, CPA., J.D.
Chief Operating Officer
Chief Operating Officer
78.75K
+215.00%
Mr. Ryan Martins
Mr. Ryan Martins
Chief Financial Officer
Chief Financial Officer
43.67K
-16.29%
Dr. Charles A. McWherter, Ph.D.
Dr. Charles A. McWherter, Ph.D.
Independent Director
Independent Director
25.00K
+150.00%
Ms. Kathleen D. Laporte
Ms. Kathleen D. Laporte
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 7月12日 週六
更新時間: 7月12日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Janus Henderson Investors
14.02%
RA Capital Management, LP
13.62%
Suvretta Capital Management, LLC
9.82%
Deep Track Capital LP
6.38%
BlackRock Institutional Trust Company, N.A.
6.19%
Other
49.97%
持股股東
持股股東
佔比
Janus Henderson Investors
14.02%
RA Capital Management, LP
13.62%
Suvretta Capital Management, LLC
9.82%
Deep Track Capital LP
6.38%
BlackRock Institutional Trust Company, N.A.
6.19%
Other
49.97%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
37.53%
Hedge Fund
27.96%
Investment Advisor
25.07%
Venture Capital
15.60%
Research Firm
2.18%
Foundation
0.79%
Individual Investor
0.62%
Bank and Trust
0.44%
Pension Fund
0.26%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
413
161.35M
110.53%
+5.77M
2025Q1
438
159.25M
109.27%
+2.99M
2024Q4
410
127.02M
92.80%
-4.94M
2024Q3
400
110.52M
105.30%
-20.72M
2024Q2
393
109.45M
113.05%
-19.16M
2024Q1
388
104.01M
113.08%
-21.73M
2023Q4
375
99.22M
108.37%
+5.43M
2023Q3
350
77.31M
106.51%
-14.51M
2023Q2
321
82.01M
116.66%
-275.98K
2023Q1
292
75.33M
112.27%
+21.64M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Janus Henderson Investors
20.46M
14.02%
+371.83K
+1.85%
Mar 31, 2025
RA Capital Management, LP
19.89M
13.62%
--
--
Mar 31, 2025
Suvretta Capital Management, LLC
14.34M
9.82%
+4.13M
+40.50%
Mar 31, 2025
Deep Track Capital LP
9.32M
6.38%
+2.84M
+43.81%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
9.03M
6.19%
+1.98M
+28.00%
Mar 31, 2025
The Vanguard Group, Inc.
7.14M
4.89%
+1.47M
+25.85%
Mar 31, 2025
Avoro Capital Advisors LLC
6.35M
4.35%
+2.25M
+54.88%
Mar 31, 2025
Citadel Advisors LLC
5.09M
3.48%
+356.98K
+7.55%
Mar 31, 2025
Pictet Asset Management Ltd.
4.20M
2.88%
+1.20M
+39.84%
Mar 31, 2025
State Street Global Advisors (US)
4.03M
2.76%
+1.09M
+36.84%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
0.92%
Harbor Health Care ETF
0.65%
First Trust Innovation Leaders ETF
0.55%
SPDR S&P Biotech ETF
0.3%
iShares Micro-Cap ETF
0.28%
Inspire Small/Mid Cap ESG ETF
0.26%
Direxion Daily S&P Biotech Bull 3X Shares
0.17%
Invesco Nasdaq Biotechnology ETF
0.16%
ProShares Ultra Nasdaq Biotechnology
0.16%
iShares Biotechnology ETF
0.14%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.92%
Harbor Health Care ETF
佔比0.65%
First Trust Innovation Leaders ETF
佔比0.55%
SPDR S&P Biotech ETF
佔比0.3%
iShares Micro-Cap ETF
佔比0.28%
Inspire Small/Mid Cap ESG ETF
佔比0.26%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.17%
Invesco Nasdaq Biotechnology ETF
佔比0.16%
ProShares Ultra Nasdaq Biotechnology
佔比0.16%
iShares Biotechnology ETF
佔比0.14%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
